Peptide epitope identification for tumor-reactive CD4 T cells

Current Opinion in Immunology

Volumn 20, Issue 2, 2008, Pages 221-227

  Kobayashi, Hiroya ^a   Celis, Esteban ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNIZATION; NONHUMAN; PROTEIN MOTIF; REVIEW; SOLID TUMOR;

ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; EPITOPES, T-LYMPHOCYTE; HUMANS; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 44749086558     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.04.011     Document Type: Review

References (55)

1. Berzofsky J.A., Terabe M., Oh S., Belyakov I.M., Ahlers J.D., Janik J.E., and Morris J.C. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113 (2004) 1515-1525
2. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188 (1998) 2357-2368
3. Rocha B., and Tanchot C. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 16 (2004) 259-263
4. Smith C.M., Wilson N.S., Waithman J., Villadangos J.A., Carbone F.R., Heath W.R., and Belz G.T. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5 (2004) 1143-1148
5. Bourgeois C., Rocha B., and Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297 (2002) 2060-2063
6. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., and Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003) 852-856
7. Giuntoli II R.L., Lu J., Kobayashi H., Kennedy R., and Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8 (2002) 922-931
8. Kennedy R., Undale A.H., Kieper W.C., Block M.S., Pease L.R., and Celis E. Direct cross-priming by Th lymphocytes generates memory cytotoxic T cell responses. J Immunol 174 (2005) 3967-3977
9. Kennedy R., and Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 177 (2006) 2862-2872. This paper provides direct evidence that CD4 T cells can prevent apoptosis induced by activation in CD8 T cells acting as 'true helper lymphocytes' and allowing the survival and persistence of memory T cells. Interestingly, rescue from apoptosis required direct interaction between CD4 and CD8 T cells and appeared to be mediated through costimulatory molecules.
10. Hahn S., Gehri R., and Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 146 (1995) 57-79
11. Haigh T.A., Lin X., Jia H., Hui E.P., Chan A.T., Rickinson A.B., and Taylor G.S. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 180 (2008) 1643-1654
12. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17 (1999) 555-561
13. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., and Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160 (1998) 3363-3373
14. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
15. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54 (2005) 187-207
16. Wang R.F., Wang X., Atwood A.C., Topalian S.L., and Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284 (1999) 1351-1354
17. Worley B.S., van den Broeke L.T., Goletz T.J., Pendleton C.D., Daschbach E.M., Thomas E.K., Marincola F.M., Helman L.J., and Berzofsky J.A. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 61 (2001) 6868-6875
18. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., Arand M., Wada H., Noguchi Y., Stockert E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187 (1998) 265-270
19. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., Mothe B.R., Chisari F.V., Watkins D.I., and Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57 (2005) 304-314
20. Kobayashi H., Wood M., Song Y., Appella E., and Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 60 (2000) 5228-5236
21. Omiya R., Buteau C., Kobayashi H., Paya C.V., and Celis E. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol 169 (2002) 2172-2179
22. Kobayashi H., Nagato T., Takahara M., Sato K., Kimura S., Aoki N., Azumi M., Tateno M., Harabuchi Y., and Celis E. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 68 (2008) 901-908
23. Kobayashi H., Nagato T., Yanai M., Oikawa K., Sato K., Kimura S., Tateno M., Omiya R., and Celis E. Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res 10 (2004) 7053-7062
24. Kobayashi H., Ngato T., Sato K., Aoki N., Kimura S., Tanaka Y., Aizawa H., Tateno M., and Celis E. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. Clin Cancer Res 12 (2006) 3814-3822. This paper describes 2 novel CD4 T cell epitopes from HTLV-I tax protein that lie proximal to CD8 T cell epitopes Notably, CD4 T cell clones specific for these epitopes could directly recognize HTLV-I tax-expressing T cell lymphoma lines.
25. Kobayashi H., Lu J., and Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61 (2001) 7577-7584
26. Kobayashi H., Song Y., Hoon D.S., Appella E., and Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61 (2001) 4773-4778
27. Kobayashi H., Omiya R., Ruiz M., Huarte E., Sarobe P., Lasarte J.J., Herraiz M., Sangro B., Prieto J., Borras-Cuesta F., et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 8 (2002) 3219-3225
28. Kobayashi H., Omiya R., Sodey B., Yanai M., Oikawa K., Sato K., Kimura S., Senju S., Nishimura Y., Tateno M., et al. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res 9 (2003) 5386-5393
29. Ruiz M., Kobayashi H., Lasarte J.J., Prieto J., Borras-Cuesta F., Celis E., and Sarobe P. Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res 10 (2004) 2860-2867
30. Kobayashi H., Nagato T., Oikawa K., Sato K., Kimura S., Aoki N., Omiya R., Tateno M., and Celis E. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 11 (2005) 3869-3878
31. Kobayashi H., Nagato T., Aoki N., Sato K., Kimura S., Tateno M., and Celis E. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 55 (2006) 850-860
32. •].
33. Parker C.E., Nightingale S., Taylor G.P., Weber J., and Bangham C.R. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol 68 (1994) 2860-2868
34. Tsai V., Southwood S., Sidney J., Sakaguchi K., Kawakami Y., Appella E., Sette A., and Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158 (1997) 1796-1802
35. Khanna R., Burrows S.R., Nicholls J., and Poulsen L.M. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28 (1998) 451-458
36. Kawashima I., Tsai V., Southwood S., Takesako K., Celis E., and Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer 78 (1998) 518-524
37. Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L., Ravagnani F., Gallino F., Belli F., and Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol 162 (1999) 1739-1748
38. Nukaya I., Yasumoto M., Iwasaki T., Ideno M., Sette A., Celis E., Takesako K., and Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 80 (1999) 92-97
39. Russo V., Tanzarella S., Dalerba P., Rigatti D., Rovere P., Villa A., Bordignon C., and Traversari C. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 97 (2000) 2185-2190
40. Gao L., Bellantuono I., Elsasser A., Marley S.B., Gordon M.Y., Goldman J.M., and Stauss H.J. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 (2000) 2198-2203
41. Keogh E., Fikes J., Southwood S., Celis E., Chesnut R., and Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167 (2001) 787-796
42. Lu J., and Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 60 (2000) 5223-5227
43. Harashima N., Kurihara K., Utsunomiya A., Tanosaki R., Hanabuchi S., Masuda M., Ohashi T., Fukui F., Hasegawa A., Masuda T., et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64 (2004) 391-399
44. Carlsson B., Totterman T.H., and Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 61 (2004) 161-170
45. Oh S., Terabe M., Pendleton C.D., Bhattacharyya A., Bera T.K., Epel M., Reiter Y., Phillips J., Linehan W.M., Kasten-Sportes C., et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 64 (2004) 2610-2618
46. •].
47. 122-140 contains within its sequence a previously defined CD8 T cell epitope. This MHC-II epitope may be the same one described in Ref. [31].
48. Knutson K.L., Schiffman K., and Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107 (2001) 477-484
49. Shirai M., Pendleton C.D., Ahlers J., Takeshita T., Newman M., and Berzofsky J.A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 152 (1994) 549-556
50. Odunsi K., Qian F., Matsuzaki J., Mhawech-Fauceglia P., Andrews C., Hoffman E.W., Pan L., Ritter G., Villella J., Thomas B., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 104 (2007) 12837-12842. The authors describe a clinical trial in ovarian cancer using a peptide from the TAA NY-ESO-1 containing a CD4 and 2 CD8 T cell epitopes. T cell clones (CD4 and CD8) from vaccinated patients were able to recognize NY-ESO-1 expressing tumor cells.
51. Bijker M.S., van den Eeden S.J., Franken K.L., Melief C.J., Offringa R., and van der Burg S.H. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179 (2007) 5033-5040. This paper demonstrates that vaccines using long synthetic peptides induce far superior immune responses than vaccines composed of the minimal CD8 T cell epitopes. The authors hypothesize that long peptides can only be presented by professional APCs, while the short, minimal epitopes may be presented by non-professional APCs, resulting in T cell anergy.
52. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190 (1999) 617-627
53. Garcia-Hernandez M.d.L., Gray A., Hubby B., and Kast W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67 (2007) 1344-1351. This reports shows remarkable anti-tumor effects of vaccination with the STEAP antigen against prostate tumors using a mouse model system, where both CD4 and CD8 T cells play a critical role.
54. Melanoma Study Group of the Mayo Clinic Cancer Center, and Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 110 (2007) 203-214. This paper describes the first clinical study using a synthetic peptide vaccine containing a naturally occurring combination of a CD4 T cell epitope and a CD8 T cell epitope.
55. Lu J., and Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 62 (2002) 5807-5812